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Abstract. Lower body lymphedema is a chronic condition and
a significant cause of morbidity following treatment of
gynecologic cancer that strongly impacts patients’ quality of life
(QoL). Most studies on secondary lymphedema have been
performed on the upper limb after breast cancer treatment and
much less is known about lower body lymphedema after
gynecologic malignancies. This review focuses on secondary
lymphedema due to gynecologic cancer treatment, analyzing its
incidence in the different types of gynecologic cancer, diagnosis,
risk factors, impact on QoL and treatment. A systematic search
of Medline has been performed to track the studies evaluating
lower body lymphedema after treatment for endometrial,
ovarian, cervical and vulvar cancer. Unfortunately, there is no
consensus about a uniform evaluation and, as a consequence,
the reported incidence is broadly different among the studies.
Standardization in lymphedema evaluation is required to better
compare the outcome of different types of treatment. 
Lower body lymphedema is a chronic condition affecting
women treated for gynecologic malignancies. It can be
asymptomatic or associated with the feeling of heaviness,
erythema and pain, often requiring lifelong treatment and
psychosocial support (1).
Lymphedema is the result of lymphatic system
insufficiency and impaired lymph transport. The core issue
is a low output failure of the lymph vascular system, leading
to a reduction of lymphatic transport below the capacity
needed to handle the load of microvascular filtrate.
Doderlein described the lymphatic drainage system of the
female genital tract in three lymphatic basins: the first includes
drainage from the vulva and the lower third of the vagina up
to the inguinofemoral nodes; the second involves the drainage
from the upper vagina and the cervix to the pelvic wall vessels
and the third the drainage from the uterine corpus and the
ovaries to the paraaortic and paracaval lymph nodes located
between the renal vessels and the inferior mesenteric artery
(2). Special attention merits the most distal external iliac
nodes, also called circumflex iliac lymph nodes, located
between the deep circumflex iliac vein and the femoral canal. 
Lymphedema related to cancer treatment arises from the
anatomical obliteration, such as after radical operative
dissection, irradiation, or from repeated lymphangitis ending
in lymphangiosclerosis (3). 
Injury to the pelvic lymphatic system affects its capacity
to absorb excess fluid and decreases membrane permeability
allowing escape of fluids, proteins and cells into extracellular
spaces with consequent swelling. Persistent edema can
determine fibrosis due to long-term parenchymal and stromal
elements proliferation and excessive deposition of
extracellular matrix, whereas protein pooling provides a
medium for cellulitis and lymphangitis (3, 4).
Lower Limb Lymphedema (LLL) is the most frequent
expression of lower body lymphedema and deserves the vast
majority of the papers on the subject. Gynecologic cancer
treatment is also associated with other sequelae involving the
lymphatic system: lymphocele, reported in around 20-30%
of patients and mostly being an incidental finding during
post-operative imaging (5) and a specific and rare subtype
of lymphedema involving genitals and mons pubis, that may
occur after gynecologic cancer treatment, mainly vulvar, but
that is mostly known as a complication of severe obesity and
of surgery and radiotherapy in males. 
Lymphadenectomy is the surgical procedure more
frequently associated with LLL.
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The therapeutic benefit of lymphadenectomy is
controversial, and the complications of this procedure must
be cautiously evaluated. Lymphadenectomy is mainly
performed for staging purposes and survival benefit is not
demonstrated (6-8). The introduction of sentinel node (SLN)
biopsy for selected cases of endometrial, cervical and vulvar
cancer is promising since it minimizes the risk of
lymphedema, it detects key nodes even when they are in
atypical locations and allows detecting small metastasis (9).
Pelvic and para-aortic lymphadenectomy are usually
performed through laparotomy. The emerging laparoscopic
approach aims at reducing surgical morbidities such as
postoperative pain, blood loss and hospital stay. Laparoscopic
lymphadenectomy is a safe and feasible procedure; however,
it is not free of complications (10) and there is no consensus
about its ability to reduce the risk of lymphedema, even though
in a recent paper the patients who underwent an open surgical
procedure experienced a higher incidence of lymphedema than
those who were treated with endoscopic surgery (11).
The diagnosis of lymphedema is challenging: signs and
symptoms are often unrecognized, and limb lymphedema can
be bilateral, thus preventing the comparison with an
unaffected leg; furthermore, adiposity (especially in obese
patients) might mask the condition. Last, but not least, poor
knowledge exists among both healthcare professionals and
patients about lymphedema and its management.
This review will focus on secondary lymphedema due to
gynecologic cancer treatment.
Search Strategy and Selection Criteria 
We conducted a systematic search of Medline using the
relevant medical subject heading search (MESH) with the
following keywords: “lymphedema”, “genital neoplasm,
female”, “ovarian neoplasms”, “vulvar neoplasms”,
“endometrial neoplasms”, “uterine cervical neoplasms”,
“surgery”, “radiotherapy”, “quality of life”. 
Only the publications written in English were considered
and original papers selected for inclusion were independently
reviewed by three Authors (VB, VZ and AD). 
No systematic reviews or concluded randomized
controlled trials (RCTs) were found; the majority of the
studies were primary research studies.
Classification 
The more frequently used system to describe lymphedema of
the limbs is the International Society of Lymphology 4-stage
classification: 
● Stage 0 (or Ia) which refers to a latent or sub-clinical
condition where swelling is not yet evident despite
impaired lymph transport, subtle changes in tissue
fluid/composition, and changes in subjective symptoms. 
● Stage I represents an early accumulation of fluid relatively
high in protein content which subsides with limb elevation. 
● Stage II means that limb elevation alone rarely reduces
tissue swelling and pitting is evident.
● Stage III encompasses lymphostatic elephantiasis where
pitting can be absent and skin changes such as acanthosis,
further deposition of fat and fibrosis, and warty
overgrowths have developed (12).
Diagnosis
Lymphedema diagnosis after gynecological cancer treatment
is often difficult since signs and symptoms can be
unrecognized, leading to inadequate referrals and treatment
delay. In most of the cases, lymphedema is diagnosed within
the first year after treatment (4, 13, 14).
The best method for LLL diagnosis has not yet been
established. However, the most accurate diagnostic method
that has been reported until now is the physical examination
performed by an experienced lymphedema specialist (15).
Objective evaluation of LLL is mostly performed by the
comparative circumferential measurement, in which one limb
is compared with the opposite in four specific points:
metatarsal-phalangeal joints, 2 cm up to the medial
malleolus, ten above and below of the patella. A unique
definition is lacking, but a circumferential difference of 2 to
2.5 cm on several levels between the two legs seems
consensual to make a diagnosis of lymphedema (16).
Unfortunately, LLL is often bilateral and proximal, since
it is due to para-aortic, bilateral pelvic or inguinal lymph
nodes dissection or irradiation. Thus, differently from what
happens for breast cancer, there is not always a reference
limb for diagnosis. Moreover, secondary lymphedema often
begins at thigh level descending towards the calf and the
foot, which can remain unaffected, in particular for a patient
with cervical cancer (13). The onset of lymphedema at distal
levels (foot and ankle) with an upward extension is not
frequent and allows an easier diagnosis. In the case of LLL
localized to feet, a specific diagnostic test consists in
pinching the skin between the second and third fingers or
between the toes; lymphedema is diagnosed if the pinched
skin does not fold up (Stemmer’s sign) (3).
Limb volume can also be evaluated by different methods.
In clinical trials, the water displacement method is widely
used, which detects volume changes of less than 1%; a
volume difference of 200 ml between the two limbs is the
cut-off point to diagnose lymphedema. This method is really
precise but difficult to use in routine practice. Optoelectronic
volumetry uses infrared light to scan limbs and estimate the
volume converting cross-sectional measurements at multiple
intervals. At last, the volume can be calculated with the
truncated cone formula: from the ankle, marks are fixed
every 4 cm up to hip; the circumference measurements of
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each cylinder are converted to volume using a specific
algorithm (17). 
Newer technologies including three-dimensional magnetic
resonance imaging (MRI) (18), lymphoscintigraphy,
computerized tomography (CT), ultrasound (19) and
bioelectrical impedance analysis are reserved for patients
with bilateral lymphedema without a definitive diagnosis or
in cases where a lymphatic obstruction is suspected for
malignancy. Lymphoscintigraphy is not commonly used, due
to the lack of standardized protocol in performing the test.
Ultrasound is useful to exclude other etiologies like deep
venous thrombosis, venous insufficiency and can also help
in identifying tissue changes and masses that might be the
cause of lymphatic compression. CT and MRI can
investigate soft tissue edema with a good sensitivity and
specificity, but they are relatively expensive (3).
With regard to subjective evaluation, general scales poorly
focus on LLL: the most widely used tool to evaluate QoL in
cancer patients is the EORTC QLQ-C30 (20). 
A specific scale for the evaluation of LLL in gynecologic
cancer patients is the Gynecologic Cancer Lymphedema
Questionnaire (GCLQ) (21) which is a 20 items self-
reporting questionnaire analyzing physical functioning
(weakness and limited movement), numbness, swelling,
infections, heaviness and aching in the previous 4 weeks.
Unfortunately, the vast majority of studies reporting the
incidence of LLL after treatment of gynecological cancer do
not use both objective and subjective evaluation tools or do
not specify the evaluation method used.
Incidence
The reported incidence of lower body lymphedema following
gynecologic cancer treatment ranges from 0 to 70% (22, 23).
Since no consensus exists on a uniform diagnostic evaluation,
the incidence is broadly different among the studies. This huge
difference may also depend on the nature of cancer, the type
of treatment, the surgical radicality, the differences in
measurement techniques and the kind of assessment used
(subjective complaints or objective clinical diagnosis).
Endometrial cancer. Endometrial cancer (EC) is the most
common gynecologic malignancy in developed countries,
and its incidence is increasing, likely because of aging
populations and rise in obesity (24). Since most cases are
diagnosed at an early stage of the disease and the prognosis
is generally favorable, these patients frequently live long
enough to develop late side-effects associated with
treatments, among which lymphedema is one of the most
debilitating. Retrospective studies have investigated its
incidence in EC using both charts revision methods (where
the condition was reported either by the physician or the
patient) and patients’ responses to questionnaires. The
incidence varies from 1.2-47%, depending on the assessment
method (25, 26). Several risk factors for the development of
lymphedema in EC have been investigated, among which
pelvic and para-aortic lymphadenectomy (27), postoperative
radiotherapy and obesity appear to play a major role. 
The higher risk of lymphedema in patients in whom a
complete pelvic and or para-aortic lymphadenectomy was
performed is reported by a recent meta- analysis (relative
risk 8.39, 95% CI=4.06-17.33 when compared to no
lymphadenectomy) (28). 
Surgery has a pivotal role in the initial treatment of EC.
The standard surgical approach is a total hysterectomy with
bilateral salpingo-oophorectomy without vaginal cuff,
performed preferably by minimally invasive techniques
(laparoscopy or robotic-assisted surgery). Lymphadenectomy
is part of the FIGO (International Federation of Gynecology
and Obstetrics) surgical staging system since the nodal status
determines prognosis and addresses adjuvant therapies.
However, the role and the extent of lymph node assessment
is controversial, particularly in early stage disease where the
risk of overtreatment is not negligible. 
Currently, a complete surgical staging is recommended in
patients with high-risk tumors (grade 3 with myometrial
invasion >50%), while it can be considered for staging
purposes in patients with intermediate risk (myometrial
invasion >50% or grade 3 with myometrial invasion <50%).
In low-risk tumors (grade 1 or 2 with myometrial invasion
<50%), lymphadenectomy is not recommended. These
recommendations are supported by the results of two RCTs
that showed no impact on survival when performing
lymphadenectomy in early-stage disease (6, 7); on the contrary
retrospective cohort studies showed opposite results (29).
Low-grade tumors occur in relatively younger and obese
patients, while high-grade tumors are seen in an older and
non-obese population set. Since obesity is a proven risk
factor for the development of lymphedema, avoiding
lymphadenectomy in these subsets of patients is of the
utmost importance for reducing the burden of LLL (30, 31).
Other lymphadenectomy-related factors that have been
considered are the number of lymph nodes removed or the
extent of the lymphadenectomy. The association between
each of these factors and the development of lymphedema is
still controversial, notably because the number of lymph
nodes removed varies greatly among the studies (26, 32, 33).
A cut-off number of lymph nodes above which
lymphedema occurs has not been clearly defined. Regarding
the distal limit of lymphadenectomy, it has been shown that
preserving the circumflex iliac lymph node is a potential
strategy to reduce the risk of developing LLL (34).
In this scenario, the SLN mapping technique has the
potential advantage to reduce the disruption of the lymphatic
channels when compared with more extensive
lymphadenectomy. It has recently gained credibility as a
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valuable staging technique, with detection rates of 81%
(95%CI=77-84) and sensitivity of 96% (95%CI=92-98), as
reported by a recent meta-analysis (35). Data on the
lymphedema risk in patients undergoing SLN mapping
technique are lacking, but scientific societies and organizations
are increasingly recognizing its utility and promising studies
are ongoing.
To briefly refer to the surgical technique in EC, the GOG
LAP-2 study reported that endoscopic surgical staging was
associated with fewer postoperative complications (including
lymphedema) compared to patients who underwent an open
procedure, and this is nowadays the standard of treatment
(36). However, in a large series of 1,087 EC patients with
severe obesity (Body Mass Index, BMI ≥40 kg/m2), no
significant differences in the rates of lymphedema were
found among minimally invasive robotic, laparoscopic or
open surgery (37). 
It should be considered that obesity itself (BMI >35
kg/m2) plays a major confounding role because, in several
studies, high BMI was an independent prognostic factor for
the development of postoperative lymphedema (11, 26, 38). 
Another area of debate about the risk factors for LLL in
EC is the association with postoperative radiotherapy. Some
studies have suggested that radiation increases the risk of
lymphedema, but most patients in these studies had more
than 20 nodes removed, which might increase the risk of
lymphedema per se (39, 40). In a recent study, the risk of
LLL after post-operative radiation (mainly external beam
radiation), evaluated through both objective and subjective
evaluations, was associated with lymph node positivity
(OR=3,2; 95%CI=1.0007-10·7; p=0.0499) when controlled
for lymph-node dissection (41). 
We can speculate that, in those patients where there is
already an alteration of the lymphatic vessels due to the
presence of metastatic or micrometastatic disease, the
fibrosis induced by radiotherapy may concur in the alteration
of the lymphatic flow, resulting in lymphedema. 
Notably, current indications for adjuvant radiotherapy are
reserved for intermediate-high risk patients, or for patients
with advanced disease (42).
Cervical cancer. Cervical cancer (CC) often affects young
women almost always diagnosed at an early stage due to the
screening widespread availability in developed countries, but
may be diagnosed at an advanced stage in the rest of the
world. It is, therefore, important to pay special attention to
the impact of treatment complications on the life ahead of
these young women. 
Radical hysterectomy with pelvic lymph node dissection
is the standard treatment for CC in FIGO stage I to stage
IIA. The incidence of LLL among the different studies
performed on CC patients undergoing this procedure ranges
from 0-55.9% (22, 40).
In women with early-stage disease (tumor size <2 cm)
who wish to preserve fertility, radical vaginal trachelectomy
with pelvic lymphadenectomy appears to be a feasible
option (43). Two studies evaluated the incidence of LLL in
patients who underwent radical trachelectomy, reporting an
incidence of 11% (44) and 24.1% (45) respectively (both
relying on subjective evaluations). In the study of Frodig et
al., women who underwent trachelectomy had persistent
LLL comparable to that experienced by patients treated with
radical abdominal hysterectomy and significantly higher
than those reported by healthy control women (p=0.031)
(44). This is not surprising as lymphadenectomy is
performed in trachelectomy as well.
Like in EC, post-operative radiotherapy is associated with a
higher risk of LLL (13, 14, 15, 39, 40, 46, 47, 48), and the
number of removed lymph nodes (40, 49) and suprafemoral
node dissection seem to be associated with a higher rate of
LLL (47).
Studies comparing laparoscopy versus laparotomy are
inconsistent: for FIGO stage IA1-IB1, LLL was reported in
3.6% of cases performed by laparotomy compared to none
in the laparoscopy group (22). Conversely, other studies
reported no differences between the laparoscopic and the
laparotomic lymphadenectomy procedure (1, 44). Comparing
abdominal radical hysterectomy versus robotic radical
hysterectomy, LLL was significantly higher in the
laparotomic group (27.5% vs. 8.3%, p=0.001) (50). 
The SLN biopsy is a promising option in order to
minimize LLL in early stage cervical cancer. Many studies
have established its feasibility, high detection rates with low
false-negative rates, in particular when SLN is detected
bilaterally. On the contrary, large tumors (>2 cm) and
lymphovascular space invasion are associated with a higher
rate of false-negative results (9, 51). However, it is not an
accepted standard of treatment as yet.
In advanced locoregional cervical cancer (FIGO stages
IIB-IVA), concurrent platin-based chemotherapy and
radiation are the standard treatment. Cisplatin also increased
radiosensitivity, reducing local recurrences and distant
metastases, leading to higher overall and disease-free
survival rates (52). Chemotherapy increased fatigue,
dyspnea, nausea, vomiting and, especially, the hematologic
toxicity, but this effect was generally moderate and reversible
with medical treatment. The incidence of late side-effects
occurring or persisting more than 60 days after the
completion of treatment, like lymphedema, bowel and
urinary dysfunction, was similar in patients treated with
radiotherapy and chemotherapy or radiotherapy alone (53).
Ovarian cancer. Ovarian cancer (OC) is the leading cause of
death among gynecologic malignancies, since diagnosis
occurs in more than 75% of cases at an advanced stage of
the disease. 
ANTICANCER RESEARCH 37: 4005-4015 (2017)
4008
Complete staging surgery including lymphadenectomy,
followed by adjuvant chemotherapy is the standard of care
for early-stage disease, while aggressive cytoreductive
surgery followed by paclitaxel/platinum-based chemotherapy
is the treatment of choice for patients with advanced stage
operable disease.
Controversy exists on the role of lymphadenectomy on
survival (54). In early stage disease, an RCT showed that
systematic lymphadenectomy is mandatory to allow
accurate staging of the tumor, but it has no influence on
either progression-free survival or overall survival (8). In
advanced-stage disease, the therapeutic value of systematic
lymphadenectomy is controversial. In a multicenter RCT
comparing systematic lymphadenectomy with bulky nodes
resection, systematic lymphadenectomy was associated
with a significant improvement in progression-free
survival, but overall survival was similar in the two arms
of treatment (55).
The reported incidence of LLL among OC patients ranges
from 4.7% to 40.8% (13, 56) and most of the studies were
performed on heterogeneous cohorts including also patients
with CC and EC (1, 13, 14, 34, 39, 40). Only one study
specifically addressed OC patients by means of subjective
evaluation (56), reporting an incidence of 40.8% (past 18.3%
and current 22.5%); LLL developed in most of the cases
(86.2%) in the first year after surgery and persisted more than
6 months after treatment in 62.1% of the women. Interestingly,
only half of the patients (52.1%) declared to be informed of
lymphedema. 
As for EC and CC, the most frequently reported risk
factors for lymphedema are a high number of removed
lymph nodes (40), cellulitis (34) and the removal of
circumflex iliac lymph nodes (34, 57). 
Lymphocele is a frequent condition after lymph -
adenectomy for OC patients. In a recent study on 800
patients who underwent pelvic and/or paraaortic
lymphadenectomy for EC, CC or OC, lymphocele was found
more frequently among OC patients (occurring in 38.2% of
the 137 OC patients, objective ultrasound evaluation).
Furthermore, OC diagnosis was an independent risk factor at
multivariate analysis both for lymphocele formation
(OR=3.137) and for being a symptomatic lymphocele
(OR=2.310) (5).
Vulvar cancer. Vulvar cancer is rather uncommon.
Treatment relies on surgery including unilateral or bilateral
groins dissection for early stage disease and combined
therapies for advanced stages. The complications most
frequently reported after treatment are wound early
breakdown or infection (20-40%) and permanent lower body
lymphedema including most of the cases of genital and
mons pubis lymphedema (30-70%) (23). Many factors
possibly associated with lower body lymphedema have been
investigated with inconsistent results. Gaarenstroom et al.
have shown that lymphedema was frequently associated
with the occurrence of early complications; conversely,
lymph node metastases, postoperative radiation, age older
than 65 years were not significant risk factors for
complications and even the separated groin incision was not
able to reduce the incidence of lymphedema (58).
Conversely, in the study of Gould et al. lower body
lymphedema was neither predicted by early complications
nor by other factors (use of antibiotics, adjuvant therapy,
drainage) (59). The rates of lymphedema were not
significantly different according to treatment modalities
(single, combination or sequence) in the study of Berger et
al. (60). According to some authors preserving the
saphenous vein during inguinal lymphadenectomy is
associated with a lower risk of lymphedema (61), but this
approach is not widely accepted. In an attempt to reduce
postoperative complications and lymphedema a study of the
topographic distribution of groin lymph nodes on 50 female
cadavers demonstrated that a radical deep femoral
lymphadenectomy can be obtained without removing the
fascia lata because the deep femoral nodes are always
located within the opening of the fossa ovalis, and no lymph
nodes are distal to the lower margin of the fossa ovalis,
under the fascia cribrosa (62). 
The SLN biopsy seems to be the most effective strategy
aimed at reducing the risk of lower body lymphedema in
patients with early-stage vulvar cancer. The GROINS V and
the GOG study reported the safety of the SLN biopsy in
selected women with vulvar cancer (23, 63). In the study of
the GOG, women with squamous cell cancer of the vulva
were eligible if the depth of invasion was at least 1 mm, the
tumor was limited to the vulva, the primary tumor size was
at least 2 cm and not larger than 6 cm and there were not any
groin lymph nodes clinically suspicious for metastases.
Women underwent SLN biopsy and inguinal femoral
lymphadenectomy, the sensitivity was 91.7% and the false-
negative rate was 3.7% (63). 
Risk Factors 
Lymphadenectomy is associated with a variable rate of
lymphedema depending on many concomitant risk factors
regarding the anatomy of the regional lymphatics, the
presence of alternate ways of lymphatic drain, the surgical
aggressiveness, the number of removed nodes, the removal
of specific nodes, the use of adjuvant radiotherapy, the
characteristics of the patient (such as BMI, comorbidities and
age). Several Authors have analyzed the association between
LLL and patient related or treatment related characteristics,
in order to define potential risk factors. Table I summarizes
the independent risk factors for the development of LLL
among gynecologic cancer survivors.
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Treatment 
Although LLL is a long-lasting and debilitating condition, it
has not been widely studied in gynecologic cancer patients
and, nowadays, there is no consensus about which is the best
treatment. On account of its chronic nature, LLL
management is lifelong, including conservative, medical and
surgical treatments. 
Patients should be referred to a specialist as soon as
possible to start a treatment, aimed at avoiding, as far as
possible, further complications such as limb deformity and
skin fibrosis.
The usual management of secondary lymphedema is
conservative, reserving operative methods for failed medical
therapies (64).
Non-operative management. Combined physical therapy
consists of a two steps program carried out by a professional
team including particularly trained lymphologists, nurses and
physiotherapists. The first step includes skin care to keep it
intact, light manual massage to avoid damage to lymphatic
vessels, exercise that, increasing muscle mass, stimulates
lymph flow and protein absorption and compression with a
multi-layered bandage. The second step adds compression
with elastic garments and manual lymph drainage when
lymphedema worsens. 
Drug therapy with diuretics and benzopyrones is helpful,
but diuretic agents must be used only for short periods in
patients with malignancy as they may cause electrolyte
imbalance. Other approaches include intermittent
pneumatic compression, thermal therapy, limb elevation,
mesotherapy and immunological therapy, but their benefit
is unclear (12, 65).
Operative management. In gynecologic cancer survivors,
surgical treatment is taken into account only when
conservative therapy has been unsuccessful. Surgical
methods resort to two approaches: physiologic and ablative
procedures. Physiologic techniques can only be performed in
early stage LLL without severe tissue changes in the affected
limb and aim to improve the rate of the lymph flow into the
venous circulation. These microsurgery techniques include
lymphatic collector implantation, vein and lymph segments
transplantation and lymphatic-venous or lymph nodal-venous
shunts. This approach has shown long-term results and
carries a low rate of complications, but the success rate is
highly variable among studies, because of limitations in
assessing the volume of the lymphedema, etiology and
postoperative management (12, 66). 
Ablative procedures should be reserved for patients with
advanced LLL, fat deposition and tissue fibrosis. They
include liposuction, which requires rigorous compliance
using compressive garments in the follow-up (12, 67) and
direct excision, which is helpful but invasive and may cause
pain, infections, healing complications, lymphatic fistulas,
necrosis of the skin graft and suboptimal cosmetic and
functional results (66).
Risk-reducing Strategies
The shortage of therapeutic strategies must address the
attention of the health care providers on preventive
techniques, in order to reduce the incidence and severity of
lower body lymphedema. 
SLN biopsy is a standard procedure for melanoma and
breast cancer, reducing surgical times, complications,
morbidity and costs. Instead, its application in gynecologic
oncology remains still controversial: SLN biopsy is a safe and
accepted alternative to inguinal femoral lymphadenectomy in
selected women with squamous early-stage (<4 cm) unifocal
vulvar cancer with no suspicious enlarged lymph nodes at
imaging (9). Several studies have demonstrated feasibility
with high detection rates and low false negative rates in
appropriately selected patients with CC or EC (68). 
Many authors maintain that removing the circumflex iliac
lymph nodes could increase the risk of postoperative
symptomatic LLL (32, 57). Hareyama et al. compared the
incidence of LLL in 2 groups of patients with OC, EC and
CC: in one group circumflex, iliac lymph nodes were
removed and in the other circumflex iliac lymph nodes were
preserved. The incidence of LLL was significantly lower in
the group with preserved nodes; furthermore, no patients in
the preserved group had lower extremity cellulitis (34). In
addition, circumflex iliac lymph nodes rarely are the regional
site of the SLN and the unique metastatic site in early stage
gynecologic malignancy (55). 
Reducing the use of external beam radiotherapy, that may
induce fibrosis preventing lymphatic reconstruction, could
reduce the risk of lower body lymphedema; however, the
results of the studies are inconsistent.
Some of the risk factors, like BMI, stage of disease, co-
morbidities can not be modified, but should be carefully
investigated and taken into account while planning treatment
strategies.  
As in breast cancer patients who underwent an axillary
dissection, a strong education on the importance of protecting
the lower extremity from infection or trauma is of the utmost
importance in reducing the risk of post-infectious
lymphedema.
Impact on Quality of Life
Gynaecologic cancer patients often experience a low QoL
due to cancer treatments, with long-term troubles regarding
sexuality, bladder and bowel functions (69). They often
report symptoms such as pain, diarrhea and lymphedema
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(70). LLL deeply impacts physical activity (71, 72) and
normal activities like walking, standing or house working.
Financial difficulties are also reported (72, 73) because of
the additional costs due to rehabilitation treatments (74),
changes of clothing to hide the appearance of swollen legs
or the compression garments (75) or to the inability to
continue the employment (73, 75). Furthermore, women with
LLL are more likely to experience symptoms of depression
or anxiety (72, 76), be less satisfied with sleep (71, 72), more
worried about a recurrence of cancer and more likely to
interpret symptoms as possible indicators of recurrence (71).
Lymphedema-induced psychological distress and the
limitation in normal movements can determine social
isolation (71, 72, 75) and loss of intimacy with the partner
(75). In the study of Ryan et al. the discovery of LLL was
described as a shock and women reported to feel alone and
betrayed (75).
Gynecologic cancer survivors with lymphedema have
higher supportive care needs in the domains of information
and symptom management as compared with those who had
no swelling (13); however, they are less likely to use
supportive care services (76). 
Dissatisfaction is reported concerning the poor knowledge
about lymphedema and its management among healthcare
professionals (75). Many patients complain of a considerable
delay in finding appropriate information and treatment (76)
and of not being informed about lymphedema risk until they
were diagnosed (13). 
Educating healthcare professionals and women is crucial
in order to detect early signals and help patients to access the
appropriate care. Information to the patients should be given
both orally and in a written format, preoperatively and before
discharge from the hospital. Teaching nurses about LLL is
important since they can discuss the problem with women,
explaining how to maintain skin integrity avoiding trauma or
infection (58). The collaboration with a lymphedema
therapist and working in a multidisciplinary team are needed
in order to manage patients with lymphedema. 
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Table I. Independent Risk Factors for the development of lower-limb lymphedema. A: In endometrial cancer patients, B: in cervical cancer patients,
C: in endometrial, cervical and ovarian cancer patients. NSAID: non-steroidal anti-inflammatory drugs; BMI: body mass index.
A-ENDOMETRIAL CANCER
Indipendent Risk Factor                                   Adjusted Odds Ratio (95%CI)        p-Value                                               Authors
Pre-cancer NSAID use                                                    1.7 (1.1-2.8)                        0.029           Beesley VL, Rowlands IJ, Hayes SC, et al. 2015 (32)
BMI at time of surgery WHO class III                      4.69 (2.71, 8.13)                     0.001            Yost KJ, Cheville AL, Al-Hilli MM, et al. 2014 (26)
Congestive heart failure                                              2.58 (1.23, 5.40)                       0.1              Yost KJ, Cheville AL, Al-Hilli MM, et al. 2014 (26)
Lymphadenectomy                                                      2.04 (1.39, 2.99)                    <0.001          Yost KJ, Cheville AL, Al-Hilli MM, et al. 2014 (26)
Number of removed lymph nodes                                           
   ≥15                                                                             18.6 (10.3-33.5)                   <0.001         Beesley VL, Rowlands IJ, Hayes SC, et al. 2015 (32)
   ≥31                                                                                2.6 (1.4-4.8)                        0.003              Todo Y, Yamamoto R, Minobe S, et al. 2010 (33)
Removal of circumflex iliac lymph nodes                   6.1 (1.3-28.5)                        0.02               Todo Y, Yamamoto R, Minobe S, et al. 2010 (33)
Adjuvant chemotherapy                                                  1.7(1.1-2.8)                         0.031           Beesley VL, Rowlands IJ, Hayes SC, et al. 2015 (32)
External beam radiation therapy                                3.00 (1.46, 6.16)                     0.003            Yost KJ, Cheville AL, Al-Hilli MM, et al. 2014 (26)
Adjuvant radiotherapy                                                   5.3 (2.2-13.1)                      0.0003             Todo Y, Yamamoto R, Minobe S, et al. 2010 (33)
B-CERVICAL CANCER
Indipendent Risk Factor                                   Adjusted Odds Ratio (95%CI)        p-Value                                               Authors
Adjuvant radiotherapy                                                 3.47 (2.08-5.78)                   <0.0001                  Kim JH, Choi JH, Ki EY, et al. 2012 (15)
                                                                                        3.7 (1.2-10.9)                       0.019                 Ohba Y, Todo Y, Kobayashi N, et al. 2011(47)
Suprafemoral node dissection                                       9.5 (1.2-73.3)                       0.031                 Ohba Y, Todo Y, Kobayashi N, et al. 2011(47)
C-ENDOMETRIAL, CERVICAL and OVARIAN CANCER
Indipendent Risk Factor                                  Adjusted Odds Ratio (95% IC)       p-Value                                               Authors
Adjuvant radiotherapy                                                 1.79 (1.20-2.67)                     0.006           Tada H, Teramukai S, Fukushima M, et al. 2009 (39)
Removal of circumflex iliac lymph nodes                 4.28 (2.09-8.77)                   <0.0001               Hareyama H, Hada K, Goto K, et al. 2015 (4)
Cellulitis                                                                       3.48 (2.03-5.98)                   <0.0001               Hareyama H, Hada K, Goto K, et al. 2015 (4)
Number of removed lymph nodes                              0.99 (0.98-0.99)                    0.038                 Hareyama H, Hada K, Goto K, et al. 2015 (4)
Conclusion
Lower body lymphedema following gynecologic cancer
treatment is a chronic condition poorly responding to any
treatment efforts, that strongly impacts QoL; special
attention must be paid in order to minimize its impact.
There is no consensus about a uniform diagnostic
evaluation and, consequently, the reported incidence of
secondary lymphedema varies among different studies. The
true prevalence of the condition is unknown, as well as the
proper management once it has been diagnosed. 
Lymphadenectomy remains the principal cause of LLL
and its adverse effects can be worsened by the other known
risk factors.
Data about the therapeutic role of lymphadenectomy in
gynecologic malignancies are still inconclusive and the
incidence and persistence of complications are well
established, therefore an evidence-based selection of the
patients that could benefit from lymphadenectomy is
strongly advocated. Surgical treatment is luckily moving
towards less invasive approaches. The reduction of the
indications to extensive lymphadenectomy and the
increasing use of SLN biopsy technique are both promising
steps in this direction.
Further studies, in particular prospective multicenter
RCTs, are needed to better elucidate the etiology,
patogenesis, diagnosis and treatment of lymphedema in
gynecologic cancer survivors. Special attention should be
devoted to stratify patients by type of cancer, surgical
approach, type of adjuvant treatment and stage of the
disease. Standardization in lymphedema evaluation is
required to compare the outcome of different treatments.
The ongoing Gynecologic Oncology Group LEG study
(GOG 244, The Lymphedema and Gynecologic Cancer
Study, NCT00956670) will help on that, providing critical
information on incidence and risk factors for lymphedema
in all gynecologic cancer patients.
Awareness about lymphedema must be encouraged both
in patients and health care providers, with the goal of
avoiding unnecessary procedures that may increase its risk
and make both actors ready to recognize it and treat it
promptly when it occurs. 
Conflicts of Interest 
All Authors disclaim any financial and personal relationships with
other people or organizations that could inappropriately influence
their work.
Acknowledgements
The Authors would like to thank Prof. Piero Sismondi for revising
the manuscript and Dr. Franco Nessi for his assistance with vascular
surgery issues.
References
1 Achouri A, Huchon C, Bats AS, Bensaid C, Nos C and Lécuru
F: Complications of lymphadenectomy for gynecologic cancer.
EJSO 39: 81-86, 2013.
2 Emons G: Significance of Lymph Node Dissection in
Gynecological Oncology. Oncol Res Treat 37: 500-504, 2014.
3 Lockwood-Rayermann S: Lymphedema in Gynecologic Cancer
Survivors. An Area for Exploration? Cancer Nurs 30: E11-18,
2007.
4 Hareyama H, Hada K and Goto K: Prevalence, Classification,
and Risk Factors for Postoperative Lower Extremity
Lymphedema in Women With Gynecologic Malignancies A
Retrospective Study. Int J Gynecol Cancer 25: 751-757, 2015.
5 Zikan M, Fischerova D, Pikakova I, Slama J, Weinberger V,
Dusek L and Cibula D: A prospective study examining the
incidence of asymptomatic and symptomatic lymphoceles
following lymphadenectomy in patients with gynecological
cancer. Gynecol Oncol 137: 291-298, 2015.
6 ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C
and Parmar MK: Efficacy of systematic pelvic
lymphadenectomy in endometrial cancer (MRC ASTEC trial): a
randomised study. Lancet 373: 125-136, 2009.
7 Benedetti Panici P, Basile S and Maneschi F: Systematic pelvic
lymphadenectomy vs. no lymphadenectomy in early-stage
endometrial carcinoma: randomized clinical trial. J Natl Cancer
Inst 100: 1707-1716, 2008.
8 Maggioni A, Benedetti Panici P, Dell’Anna T, Landoni F, Lissoni
A, Pellegrino A, Rossi RS, Chiari S, Campagnutta E, Greggi S,
Angioli R, Manci N, Calcagno M, Scambia G, Fossati R,
Floriani I, Torri V, Grassi R and Mangioni C: Randomised study
of systematic lymphadenectomy in patients with epithelial
ovarian cancer macroscopically confined to the pelvis. Br J
Cancer 95: 699-704, 2006.
9 Cibula D, Oonk MH and Abu-Rustum NR: Sentinel lymph node
biopsy in the management of gynecologic cancer. Gynecol
Oncol 136(1): 54-59, 2015.
10 Benito V, Romeu S, Esparza M, Carballo S, Arencibia O,
Medina N and Lubrano A: Safety and Feasibility Analysis of
Laparoscopic Lymphadenectomy in Pelvic Gynecologic
Malignancies. A Prospective Study. Int J Gynecol Cancer 25:
1704-1710, 2015.
11 Mendivil AA, Rettenmaier MA, Abaid LN, Brown JV, Micha JP,
Lopez KL and Goldstein BH: Lower-extremity lymphedema
following management for endometrial and cervical cancer. Surg
Oncol 25: 200-204, 2016.
12 International Society of Lymphology: The diagnosis and
treatment of peripheral lymphedema: 2013 Consensus Document
of the International Society of Lymphology. Lymphology 46: 1-
11, 2013.
13 Beesley V, Janda M, Eakin E, Obermair A and Battistutta D:
Lymphedema after gynecological cancer treatment: prevalence,
correlates, and supportive care needs. Cancer 109: 2607-2614, 2007.
14 Ryan M, Stainton MC, Slaytor EK, Jaconelli C, Watts S and
Mackenzie P: Aetiology and prevalence of lower limb
lymphoedema following treatment for gynaecological cancer.
Aust N Z J Obstet Gynaecol 43: 148-151, 2003.
15 Kim JH, Choi JH, Ki EY, Lee SJ, Yoon JH, Lee KH, Park TC,
Park JS, Bae SN and Hur SY: Incidence and Risk Factors of
Lower-Extremity Lymphedema After Radical Surgery With or
ANTICANCER RESEARCH 37: 4005-4015 (2017)
4012
Without Adjuvant Radiotherapy in Patients With FIGO Stage I
to Stage IIA Cervical Cancer. Int J Gynecol Cancer 22: 686-691,
2012.
16 Brown J: A clinically useful method for evaluating lymphedema.
Clin J Oncol Nurs 8: 35-38, 2004.
17 Deltombe T, Jamart J, Recloux S, Legrand C, Vandenbroeck N,
Theys S and Hanson P: Reliability and limits of agreement of
circumferential water displacement and optoelectronic volumetry
in the measurement of upper limb lymphedema. Lymphology 40:
26-34, 2007.
18 Liu N, Wang C and Sun M: Noncontrast three-dimensional
magnetic resonance imaging vs. lymphoscintigraphy in the
evaluation of lymph circulation disorders: a comparative study.
J Vasc Surg 41: 69-75, 2005.
19 Suehiro K, Morikage N, Murakami M, Yamashita O, Samura M
and Hamano K: Significance of ultrasound examination of skin
and subcutaneous tissue in secondary lower extremity
lymphedema. Ann Vasc Dis 6: 180-188, 2013.
20 Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A,
Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC,
Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S,
Sneeuw K, Sullivan M and Takeda F: The European
Organization for Research and Treatment of Cancer QLQ-C30:
a quality-of-life instrument for use in international clinical trials
in oncology. J Natl Cancer Inst 85: 365-337, 1993.
21 Carter J, Raviv L, Appollo K, Baser RE, Iasonos A and Barakat
RR: A pilot study using the Gynecologic Cancer Lymphedema
Questionnaire (GCLQ) as a clinical care tool to identify lower
extremity lymphedema in gynecologic cancer survivors. Gynecol
Oncol 117: 317-323, 2010.
22 Abu-Rustum NR, Gemignani ML, Moore K, Sonoda Y,
Venkatraman E, Brown C, Poynor E, Chi DS and Barakat RR:
Total laparoscopic radical hysterectomy with pelvic
lymphadenectomy using the argon-beam coagulator: pilot data and
comparison to laparotomy. Gynecol Oncol 91: 402-409, 2003.
23 Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote
I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ,
Van Dorst EB, Van der Velden J, Hermans RH, van der Putten
H, Drouin P, Schneider A and Sluiter WJ: Sentinel node
dissection is safe in the treatment of early-stage vulvar cancer.
J Clin Oncol 26: 884-889, 2008.
24 Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland
JH, Stein KD, Alteri R and Jemal A: Cancer treatment and
survivorship statistics, 2016. CA Cancer J Clin 66: 271-289, 2016.
25 Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y,
Aghajanian C, Chi DS and Barakat RR: The incidence of
symptomatic lower-extremity lymphedema following treatment
of uterine corpus malignancies: a 12-year experience at
Memorial Sloan-Kettering Cancer Center. Gynecol Oncol 103:
714-718, 2006.
26 Yost KJ, Cheville AL, Al-Hilli MM, Mariani A, Barrette BA,
McGree ME, Weaver AL and Dowdy SC: Lymphedema after
surgery for endometrial cancer: prevalence, risk factors, and
quality of life. Obstet Gynecol 124: 307-315, 2014.
27 van de Poll-Franse LV, Pijnenborg JM, Boll D, Vos MC, van den
Berg H, Lybeert ML, de Winter K and Kruitwagen RF: Health
related quality of life and symptoms after pelvic lymphadenectomy
or radiotherapy vs. no adjuvant regional treatment in early-stage
endometrial carcinoma: a large population-based study. Gynecol
Oncol 127: 153-160, 2012.
28 Frost JA, Webster KE, Bryant A and Morrison J: Lymphadenectomy
for the management of endometrial cancer. Cochrane Database Syst
Rev 9: CD007585, 2015.
29 Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton
HM, Noojin F 3rd and Conner W: Adenocarcinoma of the
endometrium: survival comparisons of patients with and without
pelvic node sampling. Gynecol Oncol 56: 29-33, 1995.
30 AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN,
Weaver AL, McGree ME, Kumar S, Keeney GL, Cliby WA and
Mariani A: Preoperative biopsy and intraoperative tumor
diameter predict lymph node dissemination in endometrial
cancer. Gynecol Oncol 128: 294-299, 2013.
31 Yanazume S, Saito T, Eto T, Yamanaka T, Nishiyama K,
Okadome M and Ariyoshi K: Reassessment of the utility of
frozen sections in endometrial cancer surgery using tumor
diameter as an additional factor. Am J Obstet Gynecol 204:
531e1-7, 2011.
32 Beesley VL, Rowlands IJ, Hayes SC, Janda M, O’Rourke P,
Marquart L, Quinn MA, Spurdle AB, Obermair A, Brand A,
Oehler MK, Leung Y, McQuire L and Webb PM; Australian
National Endometrial Cancer Study Group: Incidence, risk
factors and estimates of a woman’s risk of developing secondary
lower limb lymphedema and lymphedema-specific supportive
care needs in women treated for endometrial cancer. Gynecol
Oncol 136: 87-93, 2015.
33 Todo Y, Yamamoto R, Minobe S, Suzuki Y, Takeshi U, Nakatani
M, Aoyagi Y, Ohba Y, Okamoto K and Kato H: Risk factors for
postoperative lower-extremity lymphedema in endometrial
cancer survivors who had treatment including lymphadenectomy.
Gynecol Oncol 119: 60-64, 2010.
34 Hareyama H, Ito K, Hada K, Uchida A, Hayakashi Y, Hirayama
E, Oikawa M and Okuyama K: Reduction/prevention of lower
extremity lymphedema after pelvic and para-aortic
lymphadenectomy for patients with gynecologic malignancies.
Ann Surg Oncol 19: 268-273, 2012.
35 Smith AJB, Fader AN and Tanner EJ: Sentinel Lymph Node
Assessment in Endometrial Cancer: A Systematic Review and
Meta-analysis, American Journal of Obstetrics and Gynecology
216: 459-476, 2017.
36 Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth
JB, Mannel RS, Spiegel G, Barakat R, Pearl ML and Sharma
SK: Laparoscopy compared with laparotomy for comprehensive
surgical staging of uterine cancer: Gynecologic Oncology Group
Study LAP2. J Clin Oncol 27: 5331-5336, 2009.
37 Chan JK, Gardner AB, Taylor K, Thompson CA, Blansit K, Yu
X and Kapp DS: Robotic versus laparoscopic versus open
surgery in morbidly obese endometrial cancer patients – a
comparative analysis of total charges and complication rates.
Gynecol Oncol 139: 300-305, 2015.
38 Nicholas Z, Hu N, Ying J, Soisson P, Dodson M and Gaffney
DK: Impact of comorbid conditions on survival in endometrial
cancer. Am J Clin Oncol 37: 131-134, 2014.
39 Tada H, Teramukai S, Fukushima M and Sasaki H: Risk factors
for lower limb lymphedema after lymph node dissection in
patients with ovarian and uterine carcinoma. BMC Cancer 9: 47,
2009.
40 Biglia N, Librino A, Ottino MC, Panuccio E, Daniele A and
Chahin A: Lower limb lymphedema and neurological
complications after lymphadenectomy for gynecological cancer.
Int J Gynecol Cancer 25: 521-525, 2015.
Biglia et al: Lower Body Lymphedema (Review)
4013
41 Mitra D, Catalano PJ, Cimbak N, Damato AL, Muto MG and
Viswanathan AN: The risk of lymphedema after postoperative
radiation therapy in endometrial cancer. J Gynecol Oncol 27: e4,
2016.
42 Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín
A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR and
Sessa C and ESMO-ESGO-ESTRO Endometrial Consensus
Conference Working Group: ESMO-ESGO-ESTRO Consensus
Conference on Endometrial Cancer: diagnosis, treatment and
follow-up. Ann Oncol 27: 16-41, 2016.
43 Schneider A, Erdemoglu E, Chiantera V, Reed N, Morice P,
Rodolakis A, Denschlag D and Kesic V: Clinical
recommendation radical trachelectomy for fertility preservation
in patients with early-stage cervical cancer. Int J Gynecol Cancer
22: 659-666, 2012.
44 Frøding LP, Ottosen C, Mosgaard BJ and Jensen PT: Quality of
life, urogynecological morbidity, and lymphedema after radical
vaginal trachelectomy for early-stage cervical cancer. Int J
Gynecol Cancer 25: 699-670, 2015.
45 Lanowska M, Mangler M, Spek A, Grittner U, Hasenbein K,
Chiantera V, Hertel H, Schneider A, Köhler C and Speiser D:
Radical vaginal trachelectomy (RVT) combined with
laparoscopic lymphadenectomy: prospective study of 225
patients with early-stage cervical cancer. Int J Gynecol Cancer
21: 1458-1464, 2011.
46 Nakamura K, Kitahara Y, Satoh T, Takei Y, Takano M, Nagao S,
Sekiguchi I and Suzuki M: Analysis of the effect of adjuvant
radiotherapy on outcomes and complications after radical
hysterectomy in FIGO stage IB1 cervical cancer patients with
intermediate risk factors (GOTIC Study). World J Surg Oncol
14: 173, 2016.
47 Ohba Y, Todo Y, Kobayashi N, Kaneuchi M, Watari H, Takeda
M, Sudo S, Kudo M, Kato H and Sakuragi N: Risk factors for
lower-limb lymphedema after surgery for cervical cancer. Int J
Clin Oncol 16: 238-243, 2011.
48 Hosaka M, Watari H, Takeda M, Moriwaki M, Hara Y, Todo Y,
Ebina Y and Sakuragi N: Treatment of cervical cancer with
adjuvant chemotherapy versus adjuvant radiotherapy after
radical hysterectomy and systematic lymphadenectomy. J Obstet
Gynaecol Res 34: 552-556, 2008.
49 Füller J, Guderian D, Köhler C, Achim Schneider A and Wendt
TG: Lymphedema of the lower extremities after lymphadenectomy
and radiotherapy for cervical cancer. Strahlenther Onkol 184: 206-
211, 2008.
50 Zanagnolo V, Minig L, Rollo D, Tomaselli T, Aletti G,
Bocciolone L, Landoni F, Cardenas Rebollo JM and Maggioni
A: Clinical and oncologic outcomes of robotic versus abdominal
radical hysterectomy for women with cervical cancer.
Experience at a referral cancer center. Int J Gynecol Cancer 26:
568-574, 2016.
51 Lécuru F, Mathevet P, Querleu D, Leblanc E, Morice P, Daraï E,
Marret H, Magaud L, Gillaizeau F, Chatellier G and Dargent D:
Bilateral negative sentinel nodes accurately predict absence of
lymph node metastasis in early cervical cancer: results of the
SENTICOL study. J Clin Oncol 29: 1686-1891, 2011.
52 Chemoradiotherapy for Cervical Cancer Meta-analysis
Collaboration (CCCMAC): Reducing uncertainties about the
effects of chemoradiotherapy for cervical cancer: individual
patient data meta-analysis. Cochrane Database Syst Rev 1:
CD008285, 2010.
53 Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens
RE, Rotman M, Gershenson DM and Mutch DG: Pelvic
radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med 340: 1137-1143, 1999.
54 Mikami M: Role of lymphadenectomy for ovarian cancer. J
Gynecol Oncol 25: 279-281, 2014.
55 Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S,
Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi
S, Angioli R, Manci N, Scambia G, Dell’Anna T, Fossati R,
Floriani I, Rossi RS, Grassi R, Favalli G, Raspagliesi F,
Giannarelli D, Martella L and Mangioni C: Systematic aortic and
pelvic lymphadenectomy versus resection of bulky nodes only
in optimally debulked advanced ovarian cancer: a randomized
clinical trial. J Natl Cancer Inst 97: 560-566, 2005.
56 Lim MC, Lee JS, Nam BH, Seo SS, Kang S and Park SY: Lower
extremity edema in patients with early ovarian cancer. J Ovarian
Res 7: 28, 2014.
57 Abu-Rustum NR and Barakat RR: Observation on the role of
circumflex iliac node resection and etiology of lower extremity
lymphedema following pelvic lymphadenectomy for gynecologic
malignancy. Gynecol Oncol 106: 4-5, 2007.
58 Gaarenstroom KN, Kenter GG, Trimbos JB, Agous I, Amant F,
Peters AA and Vergote I: Postoperative complications after
vulvectomy and inguinofemoral lymphadenectomy using
separate groin incisions. Int J Gynecol Cancer 13: 522-527,
2003.
59 Gould N, Kamelle S, Tillmanns T, Scribner D, Gold M, Walker
J and Mannel R: Predictors of complications after inguinal
lymphadenectomy. Gynecol Oncol 82: 329-332, 2001.
60 Berger J, Scott E, Sukumvanich P, Smith A, Olawaiye A,
Comerci J, Kelley JL, Beriwal S and Huang M: The effect of
groin treatment modality and sequence on clinically significant
chronic lymphedema in patients with vulvar carcinoma. Int J
Gynecol Cancer 25: 119-124, 2015.
61 Zhang SH, Sood AK, Sorosky JI, Anderson B and Buller RE:
Preservation of the saphenous vein during inguinal
lymphadenectomy decreases morbidity in patients with carcinoma
of the vulva. Cancer 89: 1520-1525, 2000.
62 Borgno G, Micheletti L, Barbero M, Cavanna L, Preti M,
Valentino MC, Ghiringhello B and Bocci A: Topographic
distribution of groin lymph nodes. A study of 50 female
cadavers. J Reprod Med 35: 1127-1129, 1990.
63 Levenback CF, Ali S, Coleman RL, Gold MA, Fowler JM,
Judson PL, Bell MC, De Geest K, Spirtos NM, Potkul RK,
Leitao MM Jr, Bakkum-Gamez JN, Rossi EC, Lentz SS, Burke
JJ 2nd, Van Le L and Trimble CL: Lymphatic mapping and
sentinel lymph node biopsy in women with squamous cell
carcinoma of the vulva: a gynecologic oncology group study. J
Clin Oncol 30: 3786-3791, 2012.
64 Douglass J, Graves P and Gordon S: Self-care for management
of secondary lymphedema: a systematic review. PLoS Negl Trop
Dis 10: e0004740, 2016.
65 Korpan MI, Crevenna R and Fialka-Moser V: Lymphedema: a
therapeutic approach in the treatment and rehabilitation of cancer
patients. Am J Phys Med Rehabil 90: 69-75, 2011.
66 Basta MN, Gao LL and Wu LC: Operative treatment of
peripheral lymphedema: a systematic meta-analysis of the
efficacy and safety of lymphovenous microsurgery and tissue
transplantation. Plast Reconstr Surg 133: 905-913, 2014.
ANTICANCER RESEARCH 37: 4005-4015 (2017)
4014
67 Brorson H, Ohlin K, Olsson G, Svensson B and Svensson H:
Controlled compression and liposuction treatment for lower-
extremity lymphedema. Lymphology 41: 52-63, 2008.
68 Smith B and Backes F: The Role of Sentinel Lymph Nodes in
Endometrial and Cervical Cancer. J Surg Oncol 112: 753-760,
2015.
69 Gargiulo P, Arenare L, Pisano C, Cecere SC, Falivene S, Greggi
S, Tambaro R, Facchini G, De Palma G, Scaffa C, Della Pepa
C, Pignata S and Di Napoli M: Long-term toxicity and quality
of life in patients treated for locally advanced cervical cancer.
Oncology 90: 29-35, 2016.
70 Karabuga H, Gultekin M, Tulunay G, Yuce K, Ayhan A, Yuce D
and Yildiz F: Assessing the quality of life in patients with
endometrial cancer treated with adjuvant radiotherapy. Int J
Gynecol Cancer 25: 1526-1533, 2015.
71 Dunberger G, Helene Lindquist E, Waldenström AC, Nyberg T,
Steineck G and Åvall-Lundqvist E: Lower limb lymphedema in
gynecological cancer survivors – effect on daily life functioning.
Support Care Cancer 21: 3063–3070, 2013.
72 de Melo Ferreira AP, de Figueiredo EM, Lima RA, Cândido EB,
de Castro Monteiro MV, de Figueiredo Franco TM, Traiman P
and da Silva-Filho AL: Quality of life in women with vulvar
cancer submitted to surgical treatment: a comparative study. Eur
J Obstet Gynecol Reprod Biol 165: 91-95, 2012.
73 Kim SI, Lim MC, Lee JS, Lee Y, Park K, Joo J, Seo SS, Kang
S, Chung SH and Park SY: Impact of lower limb lymphedema
on quality of life in gynecologic cancer survivors after pelvic
lymph node dissection. Eur J Obstet Gynecol Reprod Biol 192:
31-36, 2015.
74 Finnane A, Hayes SC, Obermair A and Janda M: Quality of life
of women with lower-limb lymphedema following gynecological
cancer. Expert Rev Pharmacoecon Outcomes Res 11: 287-297,
2011.
75 Ryan M, Stainton MC, Jaconelli C, Watts S, MacKenzie P and
Mansber T: The experience of lower limb lymphedema for
women after treatment for gynecologic cancer. Oncol Nurs
Forum 30: 417-423, 2003.
76 Kusters I, Williams M, Obermair A and Janda M: Women with
self-reported lower-limb lymphedema after treatment for
gynecological cancers: are they more likely to self-report
psychosocial symptoms and less likely to use services? J
Community Support Oncol 13: 55-61, 2015.
Received May 26, 2017
Revised June 14, 2017
Accepted June 19, 2017
Biglia et al: Lower Body Lymphedema (Review)
4015
